Celltrion to deliver three treatments to Peru

South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) to Peru.

Celltrion's Truxima secured an order in tenders conducted by both the Peruvian Ministry of Health (CENARES) and Peru Social Health Insurance (EsSalud).

It will be supplied to CENARES in two installments (500mg) and to EsSalud for a year (100mg), capturing over half of the overall Peruvian market for this drug, encompassing both biosimilar and original versions.

The company also won bids for anticancer biosimilars Herzuma (trastuzumab) for breast and Yuflyma (adalimumab) for the treatment of autoimmune diseases.

These wins grant Celltrion a dominant 53% share of the Peruvian Trastuzumab market and a solid 20% share of the adalimumab market.

Celltrion plans to launch two additional biosimilars in Peru later this year: Remsima SC (subcutaneous injection for autoimmune diseases) in mid-2024 and Vegzelma (for colorectal and non-small cell lung cancer) by year-end.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com